JP2022513405A5 - - Google Patents

Info

Publication number
JP2022513405A5
JP2022513405A5 JP2021548551A JP2021548551A JP2022513405A5 JP 2022513405 A5 JP2022513405 A5 JP 2022513405A5 JP 2021548551 A JP2021548551 A JP 2021548551A JP 2021548551 A JP2021548551 A JP 2021548551A JP 2022513405 A5 JP2022513405 A5 JP 2022513405A5
Authority
JP
Japan
Prior art keywords
composition according
immune complex
subject
composition
hematological malignancy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021548551A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513405A (ja
JP7630435B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/058824 external-priority patent/WO2020092533A2/en
Publication of JP2022513405A publication Critical patent/JP2022513405A/ja
Publication of JP2022513405A5 publication Critical patent/JP2022513405A5/ja
Priority to JP2025015899A priority Critical patent/JP2025072466A/ja
Application granted granted Critical
Publication of JP7630435B2 publication Critical patent/JP7630435B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021548551A 2018-10-30 2019-10-30 抗cd123免疫複合体を用いた治療法 Active JP7630435B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025015899A JP2025072466A (ja) 2018-10-30 2025-02-03 抗cd123免疫複合体を用いた治療法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862752832P 2018-10-30 2018-10-30
US62/752,832 2018-10-30
US201962860565P 2019-06-12 2019-06-12
US62/860,565 2019-06-12
US201962881137P 2019-07-31 2019-07-31
US62/881,137 2019-07-31
PCT/US2019/058824 WO2020092533A2 (en) 2018-10-30 2019-10-30 Methods of treatment using anti-cd123 immunoconjugates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025015899A Division JP2025072466A (ja) 2018-10-30 2025-02-03 抗cd123免疫複合体を用いた治療法

Publications (3)

Publication Number Publication Date
JP2022513405A JP2022513405A (ja) 2022-02-07
JP2022513405A5 true JP2022513405A5 (cg-RX-API-DMAC7.html) 2022-11-08
JP7630435B2 JP7630435B2 (ja) 2025-02-17

Family

ID=70464182

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021548551A Active JP7630435B2 (ja) 2018-10-30 2019-10-30 抗cd123免疫複合体を用いた治療法
JP2025015899A Pending JP2025072466A (ja) 2018-10-30 2025-02-03 抗cd123免疫複合体を用いた治療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025015899A Pending JP2025072466A (ja) 2018-10-30 2025-02-03 抗cd123免疫複合体を用いた治療法

Country Status (12)

Country Link
US (2) US20200157228A1 (cg-RX-API-DMAC7.html)
EP (1) EP3873524B8 (cg-RX-API-DMAC7.html)
JP (2) JP7630435B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210087951A (cg-RX-API-DMAC7.html)
CN (2) CN113329768A (cg-RX-API-DMAC7.html)
AU (2) AU2019370291B2 (cg-RX-API-DMAC7.html)
CA (1) CA3117493A1 (cg-RX-API-DMAC7.html)
IL (1) IL282685A (cg-RX-API-DMAC7.html)
MA (1) MA54088A (cg-RX-API-DMAC7.html)
SG (1) SG11202103999VA (cg-RX-API-DMAC7.html)
TW (1) TWI870363B (cg-RX-API-DMAC7.html)
WO (1) WO2020092533A2 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020092533A2 (en) * 2018-10-30 2020-05-07 Immunogen, Inc. Methods of treatment using anti-cd123 immunoconjugates
JP7585231B2 (ja) * 2019-04-29 2024-11-18 イミュノジェン, インコーポレイテッド 抗cd123免疫複合体を含む治療的組み合わせ
US20250345449A1 (en) * 2024-05-10 2025-11-13 Immunogen, Inc. Anti-cd123 immunoconjugates for the treatment of blastic plasmacytoid cell neoplasm

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
WO2008127735A1 (en) 2007-04-13 2008-10-23 Stemline Therapeutics, Inc. Il3ralpha antibody conjugates and uses thereof
KR20100107501A (ko) 2008-01-18 2010-10-05 메디뮨 엘엘씨 부위 특이적 접합을 위한 시스테인 조작 항체
BRPI1015234A2 (en) 2009-06-22 2018-02-20 Medimmune Llc fc regions designed for site specific conjugation.
CN107753954A (zh) * 2012-12-13 2018-03-06 免疫医疗公司 功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量
EP2997044A4 (en) * 2013-05-14 2017-03-22 ImmunoGen, Inc. Anti-folr1 immunoconjugate dosing regimens
WO2015028850A1 (en) 2013-09-02 2015-03-05 Hangzhou Dac Biotech Co., Ltd Novel cytotoxic agents for conjugation of drugs to cell binding molecule
TW201709932A (zh) * 2015-06-12 2017-03-16 西雅圖遺傳學公司 Cd123抗體及其共軛物
SI3313845T1 (sl) 2015-06-29 2021-01-29 Immunogen, Inc. Konjugati spremenjenih protiteles cisteina
SMT202100092T1 (it) 2015-06-29 2021-03-15 Immunogen Inc Anticorpi anti-cd123 e loro coniugati e derivati
EP3544983A2 (en) * 2016-11-23 2019-10-02 Immunogen, Inc. Selective sulfonation of benzodiazepine derivatives
TW202021618A (zh) * 2018-08-17 2020-06-16 美商23與我有限公司 抗il1rap抗體及其使用方法
WO2020092533A2 (en) * 2018-10-30 2020-05-07 Immunogen, Inc. Methods of treatment using anti-cd123 immunoconjugates

Similar Documents

Publication Publication Date Title
JP2022505679A5 (cg-RX-API-DMAC7.html)
KR101968498B1 (ko) 암의 치료 및/또는 예방용 의약 조성물
JP2022537359A5 (cg-RX-API-DMAC7.html)
US20260028409A1 (en) Antibodies that bind to human ccr8
JP2021510736A5 (cg-RX-API-DMAC7.html)
JP2012529280A5 (cg-RX-API-DMAC7.html)
US20180037653A1 (en) Treatment for chronic lymphocytic leukemia (cll)
CN112739715A (zh) 抗cd38抗体的皮下给药
BR112013033916B1 (pt) Uso de um anticorpo específico para cd19
WO2019060750A2 (en) A33 ANTIBODY COMPOSITIONS AND METHODS OF USE IN RADIOIMMUNOTHERAPY
EP3938400A1 (en) Cd22 antibodies and methods of using the same
Castaneda-Puglianini et al. Bispecific antibodies for non-Hodgkin’s lymphomas and multiple myeloma
JP2023536631A5 (cg-RX-API-DMAC7.html)
WO2021013064A1 (zh) 一种人源化vegfr2抗体及其应用
JP2023541656A (ja) 癌を治療するための抗ilt4抗体またはそれと抗pd-1抗体との組合せの投与レジメン
JP2024533457A5 (cg-RX-API-DMAC7.html)
JP2022533009A5 (cg-RX-API-DMAC7.html)
US9580504B1 (en) Pidilizumab monoclonal antibody therapy following stem cell transplantation
AU2021381768A1 (en) Anti-gpa33 multi-specific antibodies and uses thereof
US20250101097A1 (en) Methods for treating acute myeloid leukemia with anti-ilt3 antibodies
TW202028248A (zh) 使用抗cd123免疫結合物之治療方法
CN116670285A (zh) 抗cd38抗体及其用途
EP4561623A1 (en) Methods for treating chronic myelomonocytic leukemia with anti-ilt3 antibodies
JP2023509083A (ja) 腫瘍を予防又は治療するための薬物の調製における抗cd47抗体と抗cd20抗体の組み合わせの使用
EP3487506A1 (en) Combinations of inecalcitol with an anti-cd38 agent and their uses for treating cancer